You'll hear claims that gliptins (Januvia, etc) decrease cardiovascular risk in diabetes patients

November 2011

You'll hear claims that gliptins (Januvia, etc) decrease cardiovascular risk in diabetes patients.

This is based on a new meta-analysis that suggests gliptins don't increase cardiovascular risk...and MIGHT even decrease it.

Don't buy it. It hasn't been peer-reviewed and published.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Statins prescribe GENERIC atorvastatin (Lipitor) beginning the end of November
Bisphosphonates more controversy about how long patients should take bisphosphonates (Fosamax, etc) for osteoporosis
Men's Health daily Cialis (tadalafil) for benign prostatic hyperplasia (BPH)
Men's Health Saw palmetto will fall out of favor for treating BPH symptoms
Diabetes You'll hear claims that gliptins (Januvia, etc) decrease cardiovascular risk in diabetes patients
Gastroenterology reps claim the new Duexis is safer than plain NSAIDs
Chronic Pain Gralise (gra-LEEZ), a new extended-release gabapentin for postherpetic neuralgia (PHN)
Ophthalmology Glaucoma patients often ask which drugs to avoid
Respiratory & Allergy You'll finally see Primatene Mist (epinephrine) disappear and the new Combivent Respimat appear
Edema how to handle drug-induced edema
Magnesium PPIs and hypomagnesemia are raising questions about when and how to use magnesium supplements
Infectious Diseases treatment of community-acquired pneumonia in children